CR20240046A - Anticuerpos contra el receptor alfa de la interleucina-4 humana - Google Patents

Anticuerpos contra el receptor alfa de la interleucina-4 humana

Info

Publication number
CR20240046A
CR20240046A CR20240046A CR20240046A CR20240046A CR 20240046 A CR20240046 A CR 20240046A CR 20240046 A CR20240046 A CR 20240046A CR 20240046 A CR20240046 A CR 20240046A CR 20240046 A CR20240046 A CR 20240046A
Authority
CR
Costa Rica
Prior art keywords
receptor alpha
human interleukin
alpha antibodies
antibodies
human
Prior art date
Application number
CR20240046A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Yiqing Feng
Diana Isabel Ruiz
Maya Rachel Karta
Songqing Na
David John Stokell
Laura Anne Pelletier
Donmienne Doen Mun Leung
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20240046A publication Critical patent/CR20240046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con anticuerpos que se unen específicamente a IL-4Ra humano, composiciones que comprenden tales anticuerpos IL-4Ra y métodos para usar tales anticuerpos IL-4Ra.
CR20240046A 2021-08-05 2022-08-05 Anticuerpos contra el receptor alfa de la interleucina-4 humana CR20240046A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229836P 2021-08-05 2021-08-05
US202263348388P 2022-06-02 2022-06-02
PCT/US2022/074575 WO2023015278A1 (en) 2021-08-05 2022-08-05 Human interleukin-4 receptor alpha antibodies

Publications (1)

Publication Number Publication Date
CR20240046A true CR20240046A (es) 2024-03-11

Family

ID=83193316

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240046A CR20240046A (es) 2021-08-05 2022-08-05 Anticuerpos contra el receptor alfa de la interleucina-4 humana

Country Status (15)

Country Link
US (1) US11891441B2 (es)
EP (1) EP4380979A1 (es)
JP (1) JP2024530467A (es)
KR (1) KR20240039025A (es)
AU (1) AU2022324620A1 (es)
CA (1) CA3227516A1 (es)
CL (1) CL2024000344A1 (es)
CO (1) CO2024001251A2 (es)
CR (1) CR20240046A (es)
DO (1) DOP2024000020A (es)
EC (1) ECSP24009186A (es)
IL (1) IL310419A (es)
MX (1) MX2024001644A (es)
TW (1) TW202328183A (es)
WO (1) WO2023015278A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024526428A (ja) * 2022-06-02 2024-07-18 イーライ リリー アンド カンパニー ヒトインターロイキン－４受容体アルファ抗体グルココルチコイドコンジュゲート

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2769992T (lt) * 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
JP7073487B2 (ja) 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111518211B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途

Also Published As

Publication number Publication date
CO2024001251A2 (es) 2024-03-07
US11891441B2 (en) 2024-02-06
JP2024530467A (ja) 2024-08-21
US20230064378A1 (en) 2023-03-02
CA3227516A1 (en) 2023-02-09
MX2024001644A (es) 2024-02-27
KR20240039025A (ko) 2024-03-26
TW202328183A (zh) 2023-07-16
ECSP24009186A (es) 2024-03-01
EP4380979A1 (en) 2024-06-12
IL310419A (en) 2024-03-01
CL2024000344A1 (es) 2024-08-23
AU2022324620A1 (en) 2024-06-06
WO2023015278A1 (en) 2023-02-09
DOP2024000020A (es) 2024-03-28

Similar Documents

Publication Publication Date Title
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12020500677A1 (en) Neoantigens and uses thereof
PH12020500667A1 (en) Multispecific antibodies and use thereof
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PH12021550764A1 (en) Trem2 stabilizing antibodies
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022010621A (es) Anticuerpos anti-cd19 humano.
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MY200872A (en) Antibody-Cytokine Engrafted Compositions and Methods of use for Immune Related Disorders
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
CR20240046A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
EP4023674A3 (en) Anti-il-22r antibodies
ZA202305329B (en) Multi-specific antibodies and antibody combinations
MX2023006832A (es) Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2024005683A (es) Anticuerpos contra el factor de necrosis tumoral alfa humano.
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
ZA202205813B (en) Trpv1 epitopes and antibodies